Get the Stockscreener App
1.37
4.58%
0.06
Bioxcel Therapeutics Inc stock is traded at $1.37, with a volume of 109.02M.
It is up +4.58% in the last 24 hours and down -30.46% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$1.31
Open:
$1.66
24h Volume:
109.02M
Relative Volume:
55.29
Market Cap:
$8.30M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.2231
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
-24.31%
1M Performance:
-30.46%
6M Performance:
+320.25%
1Y Performance:
+33.01%
1-Day Range:
$1.331
$2.07
1-Week Range:
$1.30
$2.07
52-Week Range:
$0.16
$6.83
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.37 | 7.93M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Reversal Confirmed BioXcel Therapeutics Inc. Stock Rallies Above MAWeekly Hot Picks With Buy Confidence Released - metal.it
How does BioXcel Therapeutics Inc. compare to its industry peersValue Investing Entry Points With Proven Results - jammulinksnews.com
BioXcel’s Strategic Moves Spark Interest - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 21%: What’s Really Driving the Move? - AInvest
Is BioXcel Stock Ready to Boom? - timothysykes.com
BioXcel stock surges after completing pivotal Phase 3 trial By Investing.com - Investing.com India
BioXcel Completes Key Trial For At-Home Agitation Drug; Stock Up In Pre-market - Nasdaq
BioXcel Completes Phase 3 Trial for BXCL501 - TipRanks
BioXcel Therapeutics Announces Last Patient Last Visit in SERENI - GuruFocus
BioXcel completes last patient visit in pivotal Phase 3 SERENITY At-Home trial. - AInvest
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
Breakthrough Phase 3 Trial Targets 23M Annual Episodes: First At-Home Treatment for Bipolar, Schizophrenia Agitation - Stock Titan
What is the dividend policy of BioXcel Therapeutics Inc. stockFinancial News Planner For Consistent Profits - jammulinksnews.com
Why is BioXcel Therapeutics Inc. stock attracting strong analyst attentionAI Powered Tips For Every Investor - jammulinksnews.com
How BioXcel Therapeutics Inc. stock performs during market volatilityAlpha Focused Technical Trade Signals Gain Attention - metal.it
Fibonacci Levels Suggest Recovery for BioXcel Therapeutics Inc.Real Trader Watchlist of Hot Stocks Released - metal.it
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Ichimoku Cloud Indicates Uncertainty Around BioXcel Therapeutics Inc.Chart Breakout Buy Signal Detection Confirmed - metal.it
BioXcel Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEntry Plan for Oversold Reversal Stocks Released - metal.it
What institutional investors are buying BioXcel Therapeutics Inc. stockPhenomenal returns - jammulinksnews.com
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Cuts Target Price to $2 - 富途牛牛
Mizuho slashes BioXcel Therapeutics stock price target to $2 from $16 - Investing.com
What is the risk reward ratio of investing in BioXcel Therapeutics Inc. stockTriple-digit wealth increases - jammulinksnews.com
What are BioXcel Therapeutics Inc. company’s key revenue driversCapitalize on market trends with confidence - jammulinksnews.com
Is it the right time to buy BioXcel Therapeutics Inc. stockUnlock daily stock market insights for success - jammulinksnews.com
What are the technical indicators suggesting about BioXcel Therapeutics Inc.Exceptional profit velocity - jammulinksnews.com
Does BioXcel Therapeutics Inc. stock perform well during market downturnsDiscover breakthrough stocks before the crowd - jammulinksnews.com
How high can BioXcel Therapeutics Inc. stock price go in 2025Free Discussion Group - metal.it
What analysts say about BioXcel Therapeutics Inc. stockFree Predictions - PrintWeekIndia
BioXcel Therapeutics Inc. Stock Analysis and ForecastRapid wealth accumulation - PrintWeekIndia
Is BioXcel Therapeutics Inc. a good long term investmentBreakthrough capital growth - PrintWeekIndia
Is BioXcel Therapeutics Inc. stock a good hedge against inflationBreakneck growth rates - jammulinksnews.com
What drives BioXcel Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada
BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results - TipRanks
BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):